BLIS Technologies Ltd
BLT
Company Profile
Business description
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).
Contact
442 Moray Place
Ground Floor
DunedinOTA9016
NZLT: +64 34740988
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2025
Employees
34
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,496.00 | 31.00 | 0.37% |
| CAC 40 | 7,393.76 | 13.02 | 0.18% |
| DAX 40 | 20,024.66 | 115.52 | 0.58% |
| Dow JONES (US) | 42,392.27 | 151.95 | -0.36% |
| FTSE 100 | 8,260.09 | 87.07 | 1.07% |
| HKSE | 19,644.21 | 20.89 | 0.11% |
| NASDAQ | 19,280.79 | 30.00 | -0.16% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,018.44 | 92.30 | -0.70% |
| S&P 500 | 5,868.55 | 13.08 | -0.22% |
| S&P/ASX 200 | 8,233.80 | 32.60 | 0.40% |
| SSE Composite Index | 3,250.81 | 11.75 | -0.36% |